Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold: SAR of the Aryloxyaryl Moiety-Reference-Cited by-同舟云学术

Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety

Published:2022-09-26 Issue:19 Volume:65 Page:12701-12724
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sainas Stefano¹^ORCID,Giorgis Marta¹^ORCID,Circosta Paola²³^ORCID,Poli Giulio⁴,Alberti Marta⁵^ORCID,Passoni Alice⁶^ORCID,Gaidano Valentina⁷^ORCID,Pippione Agnese C.¹^ORCID,Vitale Nicoletta⁸,Bonanni Davide¹⁹^ORCID,Rolando Barbara¹^ORCID,Cignetti Alessandro⁷^ORCID,Ramondetti Cristina¹⁰^ORCID,Lanno Alessia⁶^ORCID,Ferraris Davide M.⁵,Canepa Barbara¹¹,Buccinnà Barbara¹⁰^ORCID,Piccinini Marco¹⁰^ORCID,Rizzi Menico⁵,Saglio Giuseppe²⁷^ORCID,Al-Karadaghi Salam¹²^ORCID,Boschi Donatella¹^ORCID,Miggiano Riccardo⁵,Tuccinardi Tiziano³^ORCID,Lolli Marco L.¹^ORCID

Affiliation:

1. Department of Drug Science and Technology, University of Turin, Via P. Giuria 9, Turin 10125, Italy

2. Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, Turin 10043, Italy

3. Molecular Biotechnology Center, University of Turin, Via Nizza 52, Turin 10126, Italy

4. Department of Pharmacy, University of Pisa, Via Bonanno 6, Pisa 56126, Italy

5. Department of Pharmaceutical Sciences, University of Piemonte Orientale, Via G. Bovio 6, Novara 28100, Italy

6. Laboratory of Mass Spectrometry, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan 20156, Italy

7. Division of Hematology and Cell Therapy, AO Ordine Mauriziano, Largo Filippo Turati, 62, Turin 10128, Italy

8. Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, Turin 10126, Italy

9. Life Science Department, University of Modena, Via Università 4, Modena 41121, Italy

10. Department of Oncology, University of Turin, Via Michelangelo 27/B, Turin 10125, Italy

11. GEM FORLAB, Via Ing. Comotto 36, Caluso, Turin, 10014, Italy

12. Department of Biochemistry and Structural Biology, Lund University, Naturvetarvägen 14, Box 124, Lund 221 00, Sweden

Funder

Universit? degli Studi di Torino

Associazione Italiana per la Ricerca sul Cancro

Finpiemonte

Fondazione CRT

Universit? degli Studi del Piemonte Orientale

Ministero degli Affari Esteri e della Cooperazione Internazionale

Fondo Integrativo Speciale per la Ricerca

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00496

Reference65 articles.

1. Mammalian Pyrimidine Biosynthesis: Fresh Insights into an Ancient Pathway

2. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research

3. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer

4. Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy

5. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery a series of novel inhibitors of human dihydroorotate dehydrogenase: Biological activity evaluation and molecular docking;Chemical Biology & Drug Design;2023-11-05

2. Expected and unexpected products from reacting Sanger’s reagent with p-phenylenediamine;Journal of Chemical Research;2023-11

3. Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication;Antiviral Research;2023-11

4. Biochemical characterization of Mycobacterium tuberculosis dihydroorotate dehydrogenase and identification of a selective inhibitor;FEBS Letters;2023-06-15

5. Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML;International Journal of Molecular Sciences;2023-02-20